drugset
drugset / Trial / NCT03127605

Inotuzumab Ozogamicin - PF-05208773

NCT03127605 ↗

Expanded access Approved for marketing Pfizer

Summary

Inotuzumab Ozogamicin Expanded Access Program

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Inotuzumab Ozogamicin Monoclonal antibody — —

Indications

No indication recorded.